Shenzhen Neptunus Interlong Bio-technique (8329) Stock Overview
Engages in the research and development, manufacturing, and selling of medicines and medical devices in the People’s Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
8329 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Shenzhen Neptunus Interlong Bio-technique Company Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.15 |
| 52 Week High | HK$0.38 |
| 52 Week Low | HK$0.12 |
| Beta | -0.34 |
| 1 Month Change | -6.83% |
| 3 Month Change | -10.71% |
| 1 Year Change | 11.94% |
| 3 Year Change | 4.17% |
| 5 Year Change | -59.46% |
| Change since IPO | -58.90% |
Recent News & Updates
Recent updates
Shenzhen Neptunus Interlong Bio-technique Company Limited's (HKG:8329) Shares Climb 74% But Its Business Is Yet to Catch Up
Apr 16
There Is A Reason Shenzhen Neptunus Interlong Bio-technique Company Limited's (HKG:8329) Price Is Undemanding
Feb 26Is Shenzhen Neptunus Interlong Bio-technique (HKG:8329) Using Too Much Debt?
Nov 07Shenzhen Neptunus Interlong Bio-technique Company Limited's (HKG:8329) Share Price Is Matching Sentiment Around Its Earnings
Sep 05We Think You Can Look Beyond Shenzhen Neptunus Interlong Bio-technique's (HKG:8329) Lackluster Earnings
Apr 19These 4 Measures Indicate That Shenzhen Neptunus Interlong Bio-technique (HKG:8329) Is Using Debt Safely
Oct 03Is Shenzhen Neptunus Interlong Bio-technique (HKG:8329) A Risky Investment?
Mar 29We Think Shenzhen Neptunus Interlong Bio-technique (HKG:8329) Can Stay On Top Of Its Debt
Sep 28A Look At The Intrinsic Value Of Shenzhen Neptunus Interlong Bio-technique Company Limited (HKG:8329)
Aug 18Does Shenzhen Neptunus Interlong Bio-technique (HKG:8329) Have A Healthy Balance Sheet?
Jun 06Is Shenzhen Neptunus Interlong Bio-technique (HKG:8329) Using Too Much Debt?
Dec 15Shenzhen Neptunus Interlong Bio-technique's(HKG:8329) Share Price Is Down 49% Over The Past Five Years.
Dec 29Shenzhen Neptunus Interlong Bio-technique (HKG:8329) Seems To Use Debt Rather Sparingly
Nov 24Shareholder Returns
| 8329 | HK Pharmaceuticals | HK Market | |
|---|---|---|---|
| 7D | 1.4% | -3.3% | -1.8% |
| 1Y | 11.9% | 45.6% | 25.0% |
Return vs Industry: 8329 underperformed the Hong Kong Pharmaceuticals industry which returned 56% over the past year.
Return vs Market: 8329 underperformed the Hong Kong Market which returned 31.9% over the past year.
Price Volatility
| 8329 volatility | |
|---|---|
| 8329 Average Weekly Movement | 5.1% |
| Pharmaceuticals Industry Average Movement | 6.4% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in HK Market | 15.4% |
| 10% least volatile stocks in HK Market | 3.4% |
Stable Share Price: 8329 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 8329's weekly volatility has decreased from 14% to 5% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 1,474 | n/a | www.interlong.com |
Shenzhen Neptunus Interlong Bio-technique Company Limited, together with its subsidiaries, engages in the research and development, manufacturing, and selling of medicines and medical devices in the People’s Republic of China. The company offers medicines for various therapeutic areas, including oncology, cardiovascular system, respiratory system, digestive system, and mental disorders. It also involved in the purchase, sale, and distribution of medicines and healthcare food products; and research and development of biological technology business.
Shenzhen Neptunus Interlong Bio-technique Company Limited Fundamentals Summary
| 8329 fundamental statistics | |
|---|---|
| Market cap | HK$251.70m |
| Earnings (TTM) | HK$6.73m |
| Revenue (TTM) | HK$1.08b |
Is 8329 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 8329 income statement (TTM) | |
|---|---|
| Revenue | CN¥993.11m |
| Cost of Revenue | CN¥704.37m |
| Gross Profit | CN¥288.74m |
| Other Expenses | CN¥282.57m |
| Earnings | CN¥6.17m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.0037 |
| Gross Margin | 29.07% |
| Net Profit Margin | 0.62% |
| Debt/Equity Ratio | 12.8% |
How did 8329 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/17 17:51 |
| End of Day Share Price | 2025/10/17 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Shenzhen Neptunus Interlong Bio-technique Company Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.